The US House of Representatives' Energy and Commerce Committee has been on the receiving end of intense lobbying by the National Association of Chain Drug Stores to oppose a pedigree requirement, which is designed to facilitate product recalls by the Food and Drug Administration. The track-and-trace element of a bill designed to reform the federal regulator's operations, was added in an amendment by Reps Steve Buyer (Republican, Indiana) and Jim Matheson (Democrat, Utah). According to a report by the CongressDaily, the amendment is likely to be dropped at the committee stage if a consensus of members is not reached.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze